About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, June 14th, 2013

The QualityStocks
Daily Stock List


NanoTech Entertainment, Inc. (NTEK)

PennyStocks24 and Stock Analyzer reported this week on NanoTech Entertainment, Inc. (NTEK), InsideBulls, Penny Trackers, Purely Penny Stocks did earlier, and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

Headquartered in San Jose, California, NanoTech Entertainment, Inc. is a conglomerate of entertainment companies. NanoTech focuses on leveraging technology to deliver state of the art entertainment and communications products. Their markets are IPTV – Media (NanoTech Media), Gaming (NanoTech Gaming Labs), and Mobile (NanoTech Communications). NanoTech Entertainment lists on the OTC Markets. 

The Company's NanoTech Media delivers unique Television on a spectrum of platforms. NanoTech Media focuses on the emerging Internet Protocol Television (IPTV) market with an assortment of technology and content published on the Roku platform. They develop proprietary technology that they license to publishers for use in their products as well as creating and publishing innovative content.   

The Company's NanoTech Gaming Labs is a virtual manufacturer of innovative products that re-define the state of game play on the personal computer (PC) or gaming station. NanoTech Gaming Labs creates unique technology and games for the Social, Consumer, Coin-Op and Casino Markets. They operate as a virtual manufacturer, developing their technology and games, and licensing them to third parties for manufacturing and distribution. This keeps their overhead low and operations efficient.

NanoTech Communications focuses on the Mobile and Consumer space. This includes developing technology and Applications for the iPhone, iPad and Android platforms. NanoTech Communications develops and sells proprietary apps and technology.   

Earlier this month, NanoTech Entertainment announced that the Company entered into a partnership with Hannover House (HHSE) for the creation and operation of the VODWiz website and Internet Protocol Television (IPTV) channel.  VODWiz will be available on many platforms. This includes Roku, iPhone, and iPad, Android, PC and MAC. Consumers will be able to choose from the wide-ranging Hannover House library of movies ranging from Drama to Family films. 

VODWiz is built on the NanoTech Media NanoFlix platform.  The proprietary system provides users with a continuous experience across an array of platforms. Through taking advantage of the NanoTech worldwide infrastructure, VODWiz provides immediate access to customers no matter where they are situated or what device they are streaming to. 

NanoTech Entertainment, Inc. (NTEK), closed Wednesday's trading at $0.0315, up 0.43%, on 15,594,367 volume with 423 trades. The average volume for the last 60 days is 4,651,613 and the stock's 52-week low/high is $0.0005/$0.065.

Samson Oil & Gas Ltd. (SSN)

Uncommon Wisdom, Money Morning, Penny Stock Buzz, InvestorPlace, Market Authority, PickPennyStocks, Michael Stone, Research Driven Alerts, Growing Stocks Reports, and Stockdigest Report reported recently on Samson Oil & Gas Ltd. (SSN), and we highlight the Company today, here at the QualityStocks Daily Newsletter.

An independent energy company, Samson Oil & Gas Ltd. engages in the acquisition, exploration, exploitation, and development of oil and natural gas properties in the U.S. The Company holds extensive development and exploration acreage in America. They produce crude oil, natural gas, and natural gas liquids (NGL). Samson Oil & Gas has their principal office in Perth, Western Australia; they have their operations office in Denver, Colorado.

The Company is concentrating on oil production in the Niobrara and Bakken formations in the United States. Their projects include Goshen County and Sweetwater County in Wyoming; Williams County and Renville and Ward Counties in North Dakota; Roosevelt County, Montana; Lea County, New Mexico, and Onshore Gulf Coast, Texas. 

This week, Samson Oil & Gas gave an update on their operations. Concerning the South Prairie Project (Samson 25 percent non-operated working interest),  the first well to undergo drilling in the South Prairie Project, the Matson #3-1 well ( Ward County, North Dakota), has been delayed because of heavy rainfall over the last few weeks. CanElson USA (drilling contractor) was scheduled to mobilize the rig to the well site on June 10, 2013. However, CanElson has now been delayed to June 20, 2013. The Matson #3-1 well will be drilled to a total depth of 4,900 feet to test a 420-acre 4-way structural closure in the Glenburn zone of the Mississippian Mission Canyon Formation.     

Pertaining to the North Stockyard (Samson operated North Tier – Working Interest 52 percent), the Sail and Anchor 3-13-14 HBK (Horizontal Bakken) well sidetracked at 13,400 feet, which was successfully achieved. After the sidetracking of this well, drilling operations proceeded and the current measured depth is 17,350 feet (MD). The Company's intention is to drill to a total depth of approximately 18,100 feet (MD) and subsequently run the production liner. 

Samson Oil & Gas Ltd. (SSN), closed Friday's trading session at $0.45, even for the day, on 62,519 volume with 69 trades. The average volume for the last 60 days is 471,480 and the stock's 52-week low/high is $0.4101/$1.70.

Municipal Mortgage & Equity, LLC (MMAB)

Wall Street Resources reported earlier on Municipal Mortgage & Equity, LLC (MMAB), and we are highlighting the Company, here at the QualityStocks Daily Newsletter.

With corporate headquarters in Baltimore, Maryland, Municipal Mortgage & Equity, LLC is a diverse real estate finance company. The Company primarily invests in tax-exempt bonds secured by affordable housing. They specialize in tax-exempt bonds for the multi-family housing segment. Founded in 1995, Municipal Mortgage & Equity's shares trade on the OTC Markets' OTCQB. 

Municipal Mortgage & Equity (MuniMae) originates mortgage revenue bonds. State and local governments or their agencies or authorities (to finance multifamily housing developments, including affordable housing, student housing, and senior living facilities) issue these kinds of bonds. 

Furthermore, MuniMae originates other bonds, primarily municipal bonds that undergo issuance by community development districts or other municipal issuers to finance the development of community infrastructure supporting single-family housing and mixed-use and commercial developments. This infrastructure includes storm water management systems, roads, as well as community recreational facilities.  

In mid-May of this year, Municipal Mortgage & Equity announced their First Quarter 2013 results. This is for the quarter ended March 31, 2013. The Company reported common equity of $94.8 million at March 31, 2013. This represents an increase of $49.9 million from reported common equity of $44.9 million at December 31, 2012.  Comprehensive income allocable to common shareholders (includes net income and total other comprehensive income) was $50.3 million for the quarter ended March 31, 2013. This is in comparison to $11.1 million for the quarter ended March 31, 2012.  

They recorded $36.3 million of gain on the early extinguishment of debt. This resulted in their net income and their common equity to increase accordingly. Moreover, their bond portfolio grew in value by $10.8 million during the quarter ended March 31, 2013. This is in comparison to $7.0 million during the quarter ended March 31, 2012. Their common book value per share at March 31, 2013 was $2.23, versus a common book value per share at December 31, 2012 of $1.06.

Municipal Mortgage & Equity, LLC (MMAB), closed Friday's session at $1.50, up 2.74%, on 93,670 volume with 68 trades. The average volume for the last 60 days is 87,780 and the stock's 52-week low/high is $0.205/$1.55.

Infinity Augmented Reality, Inc. (ALSO)

Stock Guru, Stock Brain, HEROSTOCKS, and SmallCapVoice reported previously on Infinity Augmented Reality, Inc. (ALSO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTC Markets' OTCQB, Infinity Augmented Reality, Inc. (Infinity AR) pioneered and developed proprietary Augmented Reality Software. The Company's Augmented Reality Software enables viewing of the Real World, overlayed with Digital Images, Sound, Video and Information, as is accessible utilizing a screen, smartphone, tablet, digital glasses and other hardware. Augmented reality is a medium whereby real sensory inputs undergo enhancement, or augmentation, with relevant digital information from the Internet. Infinity AR announced yesterday that the Company is relocating their operations from New York, New York to Israel.  

With augmented reality, using specially equipped eyewear, virtual images, video, and sound are superimposed for the user over what is actually seen and heard. This heightens the real-life experience with additional information that is pertinent, informative, practical as well as entertaining. The Infinity AR Software digitally recognizes and overlays screen content using Internet Services. This includes Location Recognition, Facial Recognition, and Voice Recognition, Phone & Data Communication and Sound and more. 

The initial launch of the Infinity Augmented Reality platform will provide various applications. These include Email Management, SMS Management, and Telephone & Call Management. Therefore, the consumer will have access to all their standard Phone, Email and SMS tools. However, this will be with enhanced settings and controls. Furthermore, the Infinity Augmented Reality platform will act as a translator if a user requires this feature. 

This week, Infinity Augmented Reality (Infinity AR) announced that the Company's Chief Innovation Officer, Ms. Helen Papagiannis, was named one of The NEXT 100 Top Influencers of the Digital Industry in 2013 by the organizers of Next Berlin, a European digital conference that was held on April 23-24, 2013. NEXT Berlin is a yearly conference and intellectual salon for the European digital industry. It brings together marketing decision-makers and business developers with technical experts and creative minds. Ms. Papagiannis is a designer, consultant and researcher; she has made important contributions to the Augmented Reality (AR) sector for almost a decade.

Infinity Augmented Reality, Inc. (ALSO), closed the trading session at $0.46, up 2.22%, on 207,194 volume with 44 trades. The average volume for the last 60 days is 75,318 and the stock's 52-week low/high is $0.20/$0.73.

Implant Sciences Corp. (IMSC)

Corporate Profile Media reported recently on Implant Sciences Corp. (IMSC), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Based in Wilmington, Massachusetts, Implant Sciences Corp. is the leader in next generation Explosives Trace Detection (ETD) technology. The Company is a high technology supplier of systems and sensors. They manufacture and sell sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in their commercial explosive and narcotics trace detection systems. Implant Sciences' shares trade on the OTC Markets' OTCQB.

The Company's products undergo deployment worldwide to enhance the safety and security of their customers in areas such as aviation security, force protection, subway security, customs and immigration, cargo security, critical infrastructure protection, ports and tunnels security, and VIP protection.  

Implant Sciences develops and manufactures explosive trace detection sensors and systems capable of detecting minute amounts of a broad array of military, commercial, and homemade explosives. Their patented technologies provide innovative screening capabilities to extend and improve counter-terrorist and homeland security efforts.  

Their QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation. The Quantum Sniffer QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology. It provides quick, accurate detection of trace amounts of a broad array of military, commercial, and homemade explosives. The QS-H150 provides very high levels of operational availability. It has been proven to perform well in a broad assortment of temperatures and challenging environments. 

Implant Sciences' QS-B220 benchtop explosives and narcotics trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). It has also received TSA approval for air cargo screening.  

The Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to quickly detect and identify trace amounts of a wide array of military, commercial, and homemade explosives, as well as drugs. The QS-B220 features a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system. 

Implant Sciences, this past January, became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. 

Yesterday, Implant Sciences announced that they will exhibit their QS-B220 explosives and drugs desktop trace detector and their QS-H150 handheld explosives trace detector at booth #208 on June 16 through 18, 2013 in Greenville, South Carolina at the Adjutants General Association of the United States (AGAUS) annual conference.

Implant Sciences Corp. (IMSC), closed Friday's trading session at $1.149, up 7.38%, on 586,094 volume with 234 trades. The average volume for the last 60 days is 212,977 and the stock's 52-week low/high is $0.75/$1.84.

Sanwire Corp. (NTMG)

PennyStocks24 and Ironman Stock reported recently on Sanwire Corp. (NTMG), Real Pennies did earlier, and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, Sanwire Corp. is an international provider of wireless communications services, data solutions, and application software/hardware. Aero Networks is a wholly owned subsidiary of Sanwire. In addition, iPTerra Technologies, Inc. is a wholly owned subsidiary of Sanwire. Sanwire's focus is on the development and acquisition of world-class wireless communications companies and technologies. The Company has their corporate headquarters in Tulsa, Oklahoma. 

Sanwire's vertically integrated portfolio of solutions target a diverse spectrum of enterprises and multiple disciplines. The goal is to deliver efficient and reliable communications. The Company's Aero Networks provides advanced telecommunications and broadband services to rural communities and Native American tribes. Aero Networks' focus is on public safety, education and the healthcare sectors. Aero is a pioneer in delivering 4G/LTE, TV White Space, and advanced wireless technologies. 

Sanwire's iPTerra Technologies is a designer, developer, manufacturer, and marketer of real-time 2-way wireless and/or wireline communications, and mine-safety solutions for the worldwide mining industry. iPMine, iPTerra's flagship solution, allows mine operators to communicate (voice, text, and video), track, locate, identify, and monitor with every miner and piece of equipment in a mine. This is achievable from an office computer desktop, or from anywhere in the world with an internet connection. 

Last week, Sanwire announced that their iPTerra Technologies subsidiary established an Advisory Board and the appointment of two experienced coal mining professionals, Mr. George Naylor and Mr. John Sisk. The newly appointed Advisory Board members will help position iPTerra's underground mine communication and mine safety solutions in the coal mining market in the U.S. 

This week, Sanwire announced that their Aero Networks subsidiary opened a new office facility in Santa Fe, New Mexico. They have appointed Mr. Les Matthews as the General Manager of this new branch. The office expansion comes due to Aero Networks' planned growth in the New Mexico area and the need for a local presence.

Sanwire Corp. (NTMG), closed Friday's trading at $0.40, up 5.54%, on 238,522 volume with 34 trades. The average volume for the last 60 days is 13,765 and the stock's 52-week low/high is $0.01/$1.00.

Bison Gold Resources, Inc. (BGE.V)

Vantage Wire and Stockhouse reported previously on Bison Gold Resources, Inc. (BGE.V), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Bison Gold Resources is a mineral exploration company whose shares trade on the TSX Venture Exchange. The Company is concentrating on gold exploration; they have property assets in Manitoba, Canada. Since Quarter 3 in 2009, Bison Gold has been focusing their efforts on the advancement of their past-producing flagship Central Manitoba gold property in South East Manitoba (CM Property).

Bison Gold Resources has their headquarters in Toronto, Ontario. The Company formed via the business combination of Mid-North Resources and a group of financial professionals. Bison's principal focus is exploring high-grade gold deposits in the Province of Manitoba. The Central Manitoba property is historically the second largest gold producer in the prolific Rice Lake Greenstone Belt after San Gold Corp.'s Rice Lake Mining Operations.

In 2009, Bison Gold filed an NI 43-101 technical report concerning their CM Property, on Sedar. The Company has since commissioned Watts, Griffis and McQuat to complete an updated report that incorporates exploration data, of more than 16,152 assays that underwent testing at TSL labs in Saskatoon, Saskatchewan from their 2009-2012 exploration activities.

The CM Property produced approximately 205,000 ounces of gold up to 1951 from two main mining trends called the Central Manitoba zone and the Ogama-Rockland zone.  In Q3 2010, Bison Gold decided to focus on the resource potential next to and at depth to the old Ogama mine workings. Over the next two years, the Company drilled 74 holes, totaling 26,747 meters on the Ogama-Rockland mineralized trend. An extensive majority of the holes hit gold mineralization in at least one zone.

In 2011, Bison Gold staked mineral claims across the remaining unclaimed portion of the Ross River Pluton. It was determined that the Ross River Pluton (host rock for Ogama-Rockland trend, Eldorado, Valley and Gold Hill showings) had major potential to host high grade gold deposits. The Company staked 66 mineral claims totaling 14,629 hectares.  

Last year, Bison Gold, along with the University of Waterloo and the Manitoba Geological Survey, launched a multi-year metallogenic and structural study on the southwest portion of the Rice Lake Greenstone Belt/Ross River Pluton (host rock of the Ogama-Rockland trend). 

Bison Gold Resources, Inc. (BGE.V), closed Friday's trading session at $0.04, up 14.29%, on 1,000 volume. The stock's 52-week low/high is $0.03/$0.19.

Crocodile Gold Corp. (CRK.TO)

We are reporting on Crocodile Gold Corp. (CRK.TO), here at the QualityStocks Daily Newsletter.

Trading on the Toronto Stock Exchange, Crocodile Gold Corp. is a gold mining company with corporate headquarters in Toronto, Ontario. The Company has three operating mines in Australia and a substantial and prospective land package in the Northern Territory and the State of Victoria. Their goal is to continue production from their three operating mines while also advancing exploration programs to further organic growth. Crocodile Gold is presently mining at the Fosterville and Stawell mines in the State of Victoria. In the Northern Territory, they continue to develop their Cosmo underground mine. Crocodile Gold has a combined land package in excess of 4,000 sq. km. 

The Company has a widespread exploration program in place in the Northern Territory. They are exploring on numerous key properties on their vast land package. Their principal focus is on the Cosmo Mine, the Union Reefs, Pine Creek and Maud Creek project areas. In the State of Victoria, they have exploration programs in place designed to expand the resource base of each mine property. 

At Crocodile Gold's Northern Territory properties, the Company has 3.175 million ounces of NI 43-101 reported Measured and Indicated mineral resources and 2.14 million ounces of Inferred mineral resources. These resources are inclusive of mineral reserves. At the State of Victoria properties, Crocodile Gold has an additional 0.924 million ounces of NI 43-101 reported measured and indicated mineral resources (14.36 million tonnes at an average grade of 2.262 g/t gold) and 0.479 million ounces of inferred mineral resources (5.091 million tonnes at an average grade of 2.92 g/t gold). 

In the first quarter of 2013, Crocodile Gold produced 48,953 ounces of gold. This represents a substantial increase over the first quarter of 2012 production of 10,932 ounces of gold. This was because of the addition of the Fosterville and Stawell Gold Mines and the ramp-up of the Cosmo Mine. 

In addition, in the first quarter of 2013, the Company took the initial steps in the permitting process for the Big Hill Project with the submission of an Environmental Effect Statement (EES) referral document to the State of Victoria, Australia. Crocodile Gold and the Stawell Gold Mine have started community initiatives to engage stakeholders in the permitting process. Geotechnical drilling began and technical consultants are being engaged. Crocodile Gold is working towards a Feasibility Study (FS) for the project. The Company expects to complete the FS in the first quarter of 2014.

Crocodile Gold Corp. (CRK.TO), closed Friday's trading session at $0.175, up 2.94%, on 55,000 volume. The stock's 52-week low/high is $0.16/$0.42.


The QualityStocks
Company Corner


DoMark Internatioxnal, Inc. (DOMK)

The QualityStocks Daily Newsletter would like to spotlight DoMark International, Inc. (DOMK). Today, DoMark International, Inc. closed trading at $0.119, up 15.53%, on 2,061,717 volume with 156 trades. The stock’s average daily volume over the past 60 days is 395,321, and its 52-week low/high is $0.0322/$1.44.

DoMark International, Inc. (DOMK) is focused on researching, evaluating, and acquiring profitable private firms in the business segments of sports, technology, medical, energy, and business services. By providing the financial and human capital necessary to deal with overwhelming administrative, planning, governance, compliance, and regulatory challenges, its newly acquired partners can focus their energy and flourish.

Through its wholly owned subsidiary, SolaWerks, Inc., DoMark is committed to revolutionizing the efficiency and capabilities of a new generation of mobile devices. The subsidiary's current focus is on developing and distributing the SolaPad, a combined cover and charging system for Apple's iPad, and the SolaCase, a combined cover and charging system for all versions of Apple's iPhone.

Musclefoot, Inc., another wholly owned subsidiary of DoMark, is engaged in the distribution, marketing, and sale of Barefoot Science, the revolutionary patented foot care system designed to relieve foot and back pain as well as improve athletic performance. With a strong commitment to customer service and security, DoMark plans to expand its marketing relationships across a far broader product set.

The management team has positioned the company to capitalize on emerging opportunities by working with the world's most forward-thinking companies to develop and market game-changing products with the promise of long-term financial growth. Leveraging the expertise of its team, the company continues to evaluate acquisition candidates and products targeting underserved markets to increase its growth potential. Disclaimer

DoMark International, Inc. Blog

DoMark International, Inc. News:

DoMark International Inc. Engages Leading Global Designer to Develop a New Luxury Range of Accessory Products for the Apple iPad for the $200 Billion Luxury Product Market

DoMark International Inc. Develops New Product for $2.3 Billion iPad Accessories Market

DoMark International Inc. Positions Itself for Substantial Growth

Rainbow Coral Corp. (RBCC)

The QualityStocks Daily Newsletter would like to spotlight Rainbow Coral Corp. (RBCC). Today, Rainbow Coral Corp. closed trading at $0.325, up 16.07%, on 147,160 volume with 46 trades. The stock’s average daily volume over the past 60 days is 312,156, and its 52-week low/high is 312,156.

Rainbow Coral Corp. (RBCC), via wholly owned subsidiary Rainbow Biosciences, continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. The company specifically pursues opportunities that offer short-term marketability and commercialization potential in key areas like Alzheimer's, Parkinson's, and Cancer.

Bioscience technology is a growing, dynamic field of innovation that applies life processes to practical uses, such as the manufacturing of medical devices and the development of new bioscience procedures. From pharmaceuticals to pacemakers, genetically engineered plants to gene therapy, bioscience technology can be found virtually anywhere.

The pending joint venture with Amarantus BioScience to develop and market new therapies and treatments for neurological diseases and physical traumas is a great example of the initiatives underway. In recent news, Amarantus licensed a highly promising diagnostic blood test that could become an invaluable new tool in Alzheimer's clinical trials where patient recruitment errors occur often due to inaccurate diagnosis.

The global biotech industry, currently valued at more than $84.6B, allows new players with bright ideas to quickly grab market share and create completely new markets. The exciting initiatives being driven forward by Rainbow Coral promise to transition today's leading-edge research into practical, affordable treatments for people who need them most. Disclaimer

Rainbow Coral Corp. Company Blog

Rainbow Coral Corp. News:

RBCC Explores New Funding for Expansion

RBCC Poised To Gain Share Of $142 Billion Market

RBCC to Drive Growth Through Personalized Medicine

International Stem Cell Corp. (ISCO)

The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.248, up 7.83%, on 54,889 volume with 16 trades. The stock’s average daily volume over the past 60 days is 110,447, and its 52-week low/high is $0.161/$0.45.

International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.

A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.

In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer

International Stem Cell Corp. Company Blog

International Stem Cell Corp. News:

International Stem Cell Subsidiary Lifeline Skin Care Expands Asian Distribution

International Stem Cell Corporation Initiates IND-Enabling Study in Parkinson's Disease Program

International Stem Cell Corporation to Present at Two Upcoming Investor Conferences

VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.85, up 6.25%, on 6,300 volume with 3 trades. The stock’s average daily volume over the past 60 days is 1,581, and its 52-week low/high is $0.06/$1.52.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve.  According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months.  VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits.  In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations. 

AV-101, VistaGen's lead small molecule prodrug candidate has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.

Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data.  To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen Therapeutics and Duke University Publish Results on Production of Functional 3D Human Heart Tissue

VistaGen Announces $36 Million Strategic Financing Agreement

VistaGen Therapeutics to Present Enhancements and Expanded Validation of LiverSafe 3D™ at Society of Toxicology's 52nd Annual Meeting

DoMark International, Inc. (DOMK) Taps Biggest Players in Biggest Market

The growth of the mobile communication market has been nothing short of incredible. When Dr. Martin Cooper of Motorola made the first publicized cell phone call back in 1973, the eventual reach of the technology could hardly be appreciated. From its public introduction in the 1980s, modern mobile technology has spread to every corner of the world. Today, it’s all about smartphones and tablets, with most online activity actually coming from mobile devices.

Consider some of the following statistics, from MobiThinking.com (http://dtg.fm/VVd3):

• There are now nearly 7 billion mobile cellular subscriptions worldwide, with many developed regions actually posting more subscriptions than people as some individuals hold more than one.
• China holds the most mobile subscriptions, with over a billion, although a number of countries have a higher percentage of users.
• Global shipment of smartphones are anticipated to outnumber shipment of basic phones by more than 20 to 1 over the next two years.
• Global tablet shipments are expected to outnumber notebook shipments by more than 2 to 1, with tablet shipments topping 380 million by 2016.
• The top 3 mobile phone vendors are Samsung, Nokia, and Apple, together controlling over 50% of the market.
• China and the U.S. together represent over 40% of the global smartphone market.

The mobile communication market has been solidly embraced by DoMark International and its SolaWerks subsidiary. SolaWerks addresses the most basic and unavoidable need of mobile device users: keeping their devices charged. The company’s unique patent-pending technology, soon to be released for Apple and Samsung products, lets users charge their mobile tablet and phone devices anywhere, making use of both visible light and heat radiation to allow effective charging both outdoors and indoors without plugin.

For more information, visit www.DoMarkIntl.com

International Stem Cell Corp. (ISCO) Applies Broad Stem Cell IP Portfolio to Three Key Markets

Biotech small-cap International Stem Cell Corp. uses unfertilized eggs to develop therapies to treat diseases of the brain, liver, and the eye. By using unfertilized eggs to create human pluripotent stem cells, the company’s core technology avoids the controversial use of viable human embryos.

As noted above, the company is focused on three key markets:

The company is in pre-clinical stages for its treatment of Parkinson’s disease. Parkinson’s disease is the second most prevalent neurodegenerative diseases, effecting 4 percent of the population over the age of 50. The company says the origin of the disease and its relative localization in the brain makes this an attractive target for stem cell therapy.

Chronic liver disease, including hepatitis C, is the third most common cause of death due to chronic diseases in persons 35 to 64 years old. The company is in pre-clinical stage for its treatment of liver disease with stem-cell derived hepatocytes, a cell that makes up 70-85 percent of the liver’s cytoplasmic mass.

The company notes a large unmet medical need for the treatment of blindness with corneal tissue. Approximately 10 million people in the world are blind because of damage to their cornea. ISCO is in pre-clinical stage to produce cornea tissue implants. The company has developed and filed patents on a process that creates human corneal tissue from parthenogenetic stem cells, closely resembling a human cornea in structure and cell types.

As of April 13, 2012, the company had 90 pending patent applications across eight patent families, and three pending patents related to its skin care products. ISCO also has licensed a portfolio of 128 international patents or patent applications across 30 patent families.

For more information, visit www.internationalstemcell.com

Ventripoint Diagnostics, Inc. (VPTDF) Seeks to Expand AngeloVMS™ Applications, Triple Sales by 2014

Ventripoint Diagnostics is the creator of what company management believes to be the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. The company created the blueprint to achieve its application expansion and goals for continued financial growth, supported by key management.

The first applications of the company’s Angelo (VMS™) analysis system are congenital heart disease and pulmonary arterial hypertension. Ventripoint has been granted Canada and Europe (CE Mark) approval for the sale of VMS and is awaiting the U.S.-FDA marketing clearance as well.

VMS was developed to address several issues associated with current heart diagnostics and holds several advantages over an MRI scan. VMS procedure time is 15 minutes and is much cheaper compared to MRI or CT, in part because of the reduced office visit time. The tool eliminates the requirement of general anesthetic for children, a lengthy heart analysis process, and the need for a second trip to the hospital.

As of March 2013, Ventripoint had installed VMS in numerous research centers (10 in Europe, four in Canada, and 12 in the United States) and forecasts full-year 2013 revenue between $3 million – $5 million. The company’s goal by the year 2014 is to triple revenue to $10 million – $15 million.

Raising awareness and generating sales are obvious keys to achieving these sales goals, and in support of this, the company later this month will travel to Minneapolis, Minn., for the 24th Annual Scientific Sessions (ASE2013) where it will host a booth to present its products to attendees.

Ventripoint in December will also hold a booth at EuroEcho2012 in Istanbul, Turkey, an annual meeting that this year will focus on heart failure and imaging in interventional cardiology. Scientific minds from around the world will convene to discuss the latest research and clinical findings on the broader spectrum of echocardiography as well as other cardiovascular imaging modalities.

CEO George Adams heads the company as a serial entrepreneur and financier. Dr. Adams has 124 scientific publications and is a reviewer for major scientific journals, federal granting agencies, and Centres of Excellence.

The company in March appointed Ellen Briant as its CFO to head the company’s financial strategy as it continues to launch new products, build revenues, and seek out and establish partnerships to further grow the company.

For more information, visit www.ventripoint.com

StreamTrack, Inc. (STTK) Successfully Addresses the Fast Growing Mobile Market

StreamTrack, California-based provider of audio and video streaming services to broadcasters, is known for having made it profitable for radio stations to broadcast over the Internet. The company’s RadioLoyalty platform technology allows video advertisements to be inserted and controlled, giving advertisers a proven high-powered way to reach select audiences. The company already serves over a thousand stations, and expects its proprietary platform to continue growing in popularity.

But StreamTrack technology also serves the mobile market, with a messaging platform that is able to compress a data file consisting of several images and an audio file down to less than 100kb in size and then send that message via most mobile carriers. The system manages SMS (Short Message Service) and MMS (Multimedia Messaging Service) campaigns, MMS event boards, mobile websites, and has a detailed reporting engine. The company can also help generate opt-in mobile lists for brands, sending alerts, updates, ads, and other messages to subscribers. They can even set mobile providers up on a shared or dedicated short code, with customized keyword packages. Target audiences can be reached through iOS, Android, Blackberry, Windows, and HTML5 formats.

Mobile marketing is one of the fastest growing ways to reach the public, and RadioLoyalty means a target audience can be addressed throughout their day, at work, home, or in-between. Messages can be in the form of standard display banners, all the way up to rich media and sophisticated video ads. In addition, RadioLoyalty also offers an environment for listeners to interact with ad campaigns and content to earn Loyalty Points. It’s 100% consumer initiated, with points redeemable for merchandise within the RadioLoyalty store.

For more information, visit www.StreamTrack.com


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Real Pennies


Wall Street Profit Search


Wall Street Resources

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251